Latest Headlines

Latest Headlines

CDC green-lights GSK's meningitis vaccine for at-risk infants

A Centers for Disease Control and Prevention panel recommended the use of GlaxoSmithKline's MenHibrix vaccine for bacterial meningitis for use in babies at increased risk of infection.

J. Craig Venter explores printable vaccines

Geneticist J. Craig Venter's vision for the future of vaccines may seem a little surreal: Making available downloadable software that allows people to print a vaccine and inject it at home.

10 promising therapeutic vaccines 2012

This FierceVaccines special report spotlights 10 promising therapeutic vaccines on their way through clinical development that might just change the face of cancer treatment. Many of them are in the early steps of R&D;, so it may be a while, especially for those that are first-in-class, or that are bringing a new technology to the table, but they could be the first baby steps to a brave new world.

Takeda continues buying spree, picks up LigoCyte

Having made a series of large acquisitions that significantly broadened its reach, Japan's Takeda Pharmaceutical today announced a $60 million plus deal that seems to be filling in around the edges.

Potential allergy cure is just under the skin

Seasonal allergies may not be fatal, but are nothing to sneeze at. Fortunately, British researchers think their potential vaccine could be a cheaper and more efficient way to combat hay fever than traditional therapies already on the market.

Vaccine news a setback for Sanofi and its revenue picture

One of Sanofi's most promising vaccines, with sales estimated to push beyond $1 billion, is a treatment for four strains of the deadly dengue fever. But it got the chair knocked out from under it on that one this week when it reported the vaccine failed to protect against a strain common in Thailand.

UPDATED: Pfizer's Prevenar 13 gets shot in arm with WHO approval

Pfizer which has big expectations for its pneumococcal conjugate vaccine, has gotten a boast toward its goals with a prequalification from the World Health Organization for use of Prevenar 13 in adults over 50.

Merck's Varivax slashes U.S. chickenpox cases

Chickenpox cases in the United States plummeted almost 80% between 2000 and 2010 in 31 states, a sure sign Merck's varicella vaccine is doing its job.

Heart disease vaccine steps closer

A new study offers a glimmer of hope for a tolerogenic vaccine for heart disease, the nation's No. 1 killer. Researchers will explore a vaccine to increase the body's tolerance of a protein to stop inflammatory attacks that cause artery plaque buildup and can lead to heart disease.

Feds cut Ebola vax funding

A prophylactic vaccine to prevent the onset of infection of the lethal Ebola virus may never come to fruition, an expert told the BBC, following a rash of Ebola cases in Uganda that killed at least 16 people.